1 Apr 2016

Acquisition of own shares April 1, 2016

Read More
24 Mar 2016

Nominations for new members of UCB's Board of Directors

Read More
23 Mar 2016

UCB Announces Results from First Head-to-Head study of Cimzia® (certolizumab pegol) and Humira® (adalimumab) in Bio-Naïve Rheumatoid Arthritis Patients

Read More
21 Mar 2016

UCB and Amgen announce positive topline results from phase 3 study evaluating romosozumab in men with osteoporosis

Read More
26 Feb 2016

UCB with progress on its growth path delivering value to patients and shareholders

Read More
22 Feb 2016

UCB And Amgen Announce Positive Topline Results From The Phase 3 Study Of Romosozumab in Postmenopausal Women With Osteoporosis

Read More
19 Feb 2016

U.S. FDA approves UCB’s new epilepsy treatment, BRIVIACT®, for patients with partial-onset seizures

Read More
8 Feb 2016

UCB and Baylor College of Medicine launch strategic alliance in neurodegeneration

Read More
19 Jan 2016

UCB’s new epilepsy drug BRIVIACT® receives EU approval 

Read More
14 Jan 2016

UCB’s Executive Committee welcomes a new member

Read More
Subscribe to